Coy Heldermon, MD
Medical Oncology · Gainesville, FLNPI 1467474502
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (52.6%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Sanofi accounts for 65.5% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2019 at $20,056 and has fallen 86.7% since, to $2,675 in 2025.
Across 20 payments — averaging $2096.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$27K
- Chiesi USA, Inc.$14K
- AstraZeneca$350
- Puma Biotechnology, Inc.$50
- Gilead$12
Across 30 payments — averaging $16,837 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$204K
- Mallinckrodt Hospital Products Inc.$168K
- Mallinckrodt Enterprises LLC$133K
What the payments were for
- Consulting fees$22,07153%
- Speaking & faculty fees$9,70423%
- Grants$3501%
- Travel & lodging$9,44723%
- Food & beverage$3361%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 15 | $27,454 |
| Chiesi USA, Inc. | 2 | $14,054 |
| AstraZeneca | 1 | $350 |
| Puma Biotechnology, Inc. | 1 | $50 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$41,921 in reported general payments places this provider in the 80th percentile of 507 medical oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 30 | $464,438 |
| VerzenioAbemaciclib | 28 | $413,014 |
| FabrazymeAgalsidase Beta | 22 | $280,849 |
| Letrozole | 420 | $11,309 |
| Exemestane | 17 | $4,989 |
| Anastrozole | 33 | $913 |
| Ibandronate Sodium | 19 | $833 |
| Tamoxifen Citrate | 34 | $808 |
| Oxybutynin Chloride ErOxybutynin Chloride | 17 | $656 |
| Prochlorperazine Maleate | 16 | $401 |
| Oxycodone Hcl | 27 | $345 |
| Ondansetron Hcl | 20 | $343 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 12 | $198 |
| Dexamethasone | 14 | $152 |
| Duloxetine Hcl | 11 | $123 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| SanofiFabrazyme | $27,454 | $280,84922 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 507 medical oncology providers in Florida.
Other medical oncology in Gainesville
- John WingardGainesville$106K
- Vijay PatelGainesville$72K
- Neil LoveMiami$5.6M
- Mahdi TahaBoca Raton$1.7M
- Raji ShameemOrlando$1.3M
- Mohammad JahanzebBoca Raton$1.3M
- Michel VelezOrlando$927K
- Yuanbin ChenOrlando$810K
- Reshma MahtaniPlantation$608K
- Rebecca MorooseOrlando$543K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.